Abstract
Purpose In the United States, breast cancer clinical risk assessments are inconsistent and inequitable. The previous success of BRCA1 and BRCA2 screening has demonstrated that genetics could be used to reduce these inequities, if they are available and accessible across the population. The aim of this study is to evaluate the performance of different genetic screening approaches to identify women at high-risk of breast cancer in the general population.
Methods We did a retrospective study on 25,591 women participating in the Healthy Nevada Project. Electronic Health Records (EHR) data were used to identify women with a family history of, and women who were diagnosed with breast cancer. The genetic analysis assessed the role of rare predicted loss-of-function (pLOF) variants in BRCA1, BRCA2, PALB2, ATM and CHEK2, as well as the combined role of common variants via a polygenic risk score. Women were considered at high-risk of breast cancer if they had greater than 20% probability of being diagnosed with breast cancer by age 70.
Results Family history of breast cancer (FHx-BrCa) was ascertained on or after the record of breast cancer for 78% of women with both, indicating that this method for risk assessment is not being properly utilized for early screening. Genetics offered an alternative method for risk assessment. 11.4% of women in HNP were at high-risk of breast cancer based on their genetic risk: having a pLOF variant in BRCA1, BRCA2 or PALB2 (hazard ratio = 10.4, 95% confidence interval: 8.1-13.5), or a pLOF variant in ATM or CHEK2 (HR = 3.4, CI: 2.4-4.8), or being in the top 10% of the polygenic risk score distribution (HR = 2.4, CI: 2.0-2.8). We also showed that combining PRS with pLOF in ATM and CHEK2 allowed a better identification of participants with high risk while minimizing false positives. Women with a pLOF in ATM or CHEK2 and in the top 50% of the PRS are at high risk (39.2% probability of breast cancer at age 70), while those with a pLOF in ATM or CHEK2 and in the bottom 50% of the PRS are not at high risk (14.4% probability of breast cancer at age 70).
Conclusion These results suggest that a combined monogenic and polygenic approach may best capture the inherited risk for breast cancer across the population.
Competing Interest Statement
A.B., K.M.S.B., I.T., N.T., R.J., N.L.W., M.J.F., C.H. and E.T.C. are employees of Helix. A patent application has been filed by Helix for the 'Dynamic risk management for breast cancer based on multi-factor genetic testing' with A.B. and J.J.G. as inventors, and its current status is unpublished (application number 63/467,250).
Funding Statement
Funding was provided to the Renown Institute for Health Innovation by Renown Health and the Renown Health Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Healthy Nevada Project study was reviewed and approved by the University of Nevada, Reno Institutional Review Board (project 956068-12). All participants gave their informed consent before participation. All data used for research were de-identified.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The Healthy Nevada Project data are available to qualified researchers upon request and with permission of the Institute for Health Innovation (IHI) and Helix. Researchers who would like to obtain the raw genotype data related to this study will be presented with a data user agreement, which requires that no participants will be reidentified and no data will be shared between individuals or uploaded onto public domains. The IHI encourages and collaborates with scientific researchers on an individual basis. Examples of restrictions that will be considered in requests to data access include but are not limited to (1) whether the request comes from an academic institution in good standing and will collaborate with our team to protect the privacy of the participants and the security of the data requested, (2) type and amount of data requested, (3) feasibility of the research suggested, and (4) amount of resource allocation for the IHI and Renown Hospital required to support the collaboration. Any correspondence and data availability requests related to Healthy Nevada Project should be addressed to J.J.G. (Joe.Grzymski{at}dri.edu) or Craig Kugler (Craig.Kugler{at}dri.edu).
